Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 7/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 5/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.30 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18393090 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1ELANETK1KIF11 | |
| SCHEMBL14929394 | 0.81 | — | — | |
| SCHEMBL13702037 | 0.78 | TSHR (0.43) | MEN1KMT2A | |
| SCHEMBL14328919 | 0.78 | — | — | |
| SCHEMBL14124053 | 0.76 | — | — | |
| SCHEMBL23405178 | 0.75 | SMYD2 (0.38) | CYP3A4MAPK1 | |
| SCHEMBL15685349 | 0.75 | SMYD2 (0.38) | CYP3A4MAPK1 | |
| SCHEMBL14328899 | 0.75 | SMYD2 (0.38) | CYP3A4MAPK1 | |
| SCHEMBL19503367 | 0.75 | — | — | |
| SCHEMBL19464907 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732902-B1 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7405214-B2 | Nucleoside derivatives and therapeutic use thereof | REXAHN CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1732902-A2 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | Rexahn Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097757-A2 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222185-A1 | Nucleoside derivatives and therapeutic uses therof | REXAHN CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222185-A1 | Nucleoside derivatives and therapeutic uses therof | TYMP, NUDT1, HPRT1 | CYP3A4 4617/4885MAPK1 3530/4885ELANE 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.